{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-075880","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.448718+00:00","generated_at":"2026-06-01T02:47:52.142989+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acasti Pharma FY2024 net loss $12.9M; STRIVE-ON trial on track for NDA in H1 2025","bullets":["FY2024 net loss $12.9M ($1.35 per share), down from $42.4M in FY2023; decrease due to prior year impairments not recurring and restructuring.","R&D expenses fell to $4.7M from $10.0M; G&A expenses down to $6.4M from $7.6M reflecting strategic realignment toward GTX-104.","Cash and equivalents $23.0M as of March 31, 2024; projected runway into Q2 2026.","STRIVE-ON Phase 3 safety trial enrollment on track; potential NDA submission to FDA in first half of 2025.","Completed $7.5M private placement in September 2023; deprioritized GTX-102 and GTX-101 to focus on GTX-104."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-075880","json":"https://secwatch.observer/filing/0000950170-24-075880.json","markdown":"https://secwatch.observer/filing/0000950170-24-075880.md","text":"https://secwatch.observer/filing/0000950170-24-075880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024075880/0000950170-24-075880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024075880/acst-20240621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:47:52.142989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}